Pharmacy Times

Generic Times Product News


Alprazolam Extended-release Tablets

Marketed by: Teva Pharmaceuticals USA (North Wales, PA)

Compared to: Xanax XR (Pfizer)

Indication: June 4, 2007?Teva Pharmaceuticals USA announced the introduction and availability of Alprazolam Extended-release Tablets, CIV. Alprazolam is a triazolo analogue of the 1,4 benzodiazepine class of central nervous system?active compounds. These tablets are indicated for the treatment of panic disorder, with or without agoraphobia. Panic disorder is characterized by recurrent unexpected panic attacks?a discrete period of intense fear or discomfort in which symptoms develop abruptly and reach a peak within 10 minutes.

Dosage Form: Tablets: 0.5, 1, 2, and 3 mg

For More Information: www.tevausa.com, 888-TEVA USA (888-838-2872)


 Benzphetamine HCl CII 50-mg Tablets

Marketed by: Paddock Laboratories Inc. (Minneapolis, MN)

Compared to: Didrex (Pfizer)

Indication: June 4, 2007?Paddock Laboratories announced the introduction of Benzphetamine HCl CII 50-mg Tablets. These tablets are indicated for the treatment of exogenous obesity as a short-term adjunct in a regimen of weight reduction based on caloric restriction. Each tablet contains 50 mg of the anorectic agent benzphetamine hydrochloride. Dosage should be individualized according to the response of the patient. The suggested dosage ranges from 25 to 50 mg, 1 to 3 times daily.

Dosage Form: Tablets: 50 mg

For More Information: www.paddocklabs.com, 800-328-5113


Nifedipine Extended-release Tablets

Marketed by: Actavis (Hafnarfjordur, Iceland)

Compared to: Adalat CC (Bayer HealthCare)

Indication: June 26, 2007?Actavis announced that it launched Nifedipine Extended-release Tablets. These tablets are the generic equivalent of Bayer HealthCare?s Adalat CC tablets and are indicated for the treatment of hypertension and coronary heart disease: chronic stable angina pectoris. The product may be used alone or in combination with other antihypertensive agents. Dosage amounts are based on the patient?s needs; therapy is usually initiated with one 30- or 60-mg tablet swallowed whole once daily.

Dosage Form: Tablets: 30 and 60 mg

For More Information: www.actavis.com


Simvastatin Tablets 10, 20, 40, and 80 mg

Marketed by: Lupin Pharmaceuticals Inc. ((Baltimore, MD)

Compared to: Zocor (Merck)

Indication: May 15, 2007?Lupin Pharmaceuticals announced that it received final FDA approval for its abbreviated new drug application for Simvastatin Tablets 10, 20, 40, and 80 mg. Simvastatin tablets are indicated for the treatment of high cholesterol. This lipid-lowering agent may be used to reduce the risk of coronary heart disease mortality and cardiovascular events; in patients with hypercholesterolemia requiring modifications of lipid profiles; and in adolescent patients with heterozygous familial hypercholesterolemia. Prior to initiating therapy with simvastatin, secondary causes for hypercholesterolemia (eg, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile should be performed to measure total cholesterol, high-density lipoprotein, and triglycerides.

Dosage Form: Tablets: 10, 20, 40, and 80 mg

For More Information: www.lupinpharmaceuticals.com (800-466-1450)